Ashlynn Davis, APRN
Psychiatric/Mental Health, Adult · Lafayette, INNPI 1386386985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 74 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$319
- Teva Pharmaceuticals USA, Inc.$230
- Johnson & Johnson$142
- AbbVie$136
- Alkermes, Inc.$127
- E.r. Squibb & Sons, L.L.C.$80
- plus $305 from 8 others
What the payments were for
- Food & beverage$1,26094%
- Education$786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $319 |
| Teva Pharmaceuticals USA, Inc. | 15 | $230 |
| Johnson & Johnson | 5 | $142 |
| AbbVie | 8 | $136 |
| Alkermes, Inc. | 8 | $127 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Lundbeck LLC | 3 | $65 |
| Neurocrine Biosciences, Inc. | 4 | $62 |
| Indivior Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Corium, LLC | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $16 |
How this compares
Too few psychiatric/mental health, adult providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 195 | $681,737 |
| AustedoDeutetrabenazine | 93 | $531,683 |
| VraylarCariprazine Hcl | 150 | $208,144 |
| Abilify MaintenaAripiprazole | 50 | $142,635 |
| IngrezzaValbenazine Tosylate | 12 | $89,473 |
| AristadaAripiprazole Lauroxil | 13 | $40,882 |
| TrintellixVortioxetine Hydrobromide | 90 | $34,586 |
| RexultiBrexpiprazole | 21 | $31,181 |
| LatudaLurasidone Hcl | 11 | $29,656 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $27,650 |
| BelsomraSuvorexant | 59 | $26,666 |
| Clozapine | 402 | $24,556 |
| Risperdal ConstaRisperidone Microspheres | 13 | $20,040 |
| QelbreeViloxazine Hcl | 19 | $12,611 |
| Chlorpromazine Hcl | 73 | $10,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $142 | $701,777208 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $230 | $531,68393 claims |
| AbbVieVraylar | $136 | $208,144150 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $319 | $173,81671 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $62 | $89,47312 claims |
| Alkermes, Inc.Aristada, Lybalvi | $127 | $68,53231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Lafayette
- Julia FonteCarmel$21K
- Lyndsay HillIndianapolis$6K
- Thelma Young-BoldenBloomington$6K
- Deborah BykowskiCarmel$3K
- Noreen NowakIndianapolis$2K
- Cynthia WilsonCarmel$2K
- Mary HessionIndianapolis$1K
- Jane NewkirkIndianapolis$1K
- Leah KnightIndianapolis$1K
- Valerie MarkleyTerre Haute$732
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.